Walker D J, Pitsch J L, Peng M M, Robinson B L, Peters W, Bhisutthibhan J, Meshnick S R
Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan 48109, USA.
Antimicrob Agents Chemother. 2000 Feb;44(2):344-7. doi: 10.1128/AAC.44.2.344-347.2000.
Artemisinin and its derivatives are important new antimalarials which are now used widely in Southeast Asia. Clinically relevant artemisinin resistance has not yet been reported but is likely to occur. In order to understand how the malaria parasite might become resistant to this drug, we studied artemisinin resistance in the murine malaria parasite Plasmodium yoelii. The artemisinin-resistant strain (ART), which is approximately fourfold less sensitive to artemisinin than the sensitive NS strain, accumulated 43% less radiolabeled drug in vitro (P < 0.01). Within the parasite, the drug appeared to react with the same parasite proteins in both strains. The translationally controlled tumor protein, one of the artemisinin target proteins, did not differ between the strains. No DNA sequence difference was found, but the resistant strain was found to express 2.5-fold-more protein than the sensitive strain (P < 0.01). Thus, the phenotype of artemisinin resistance in P. yoelii appears to be multifactorial.
青蒿素及其衍生物是重要的新型抗疟药物,目前在东南亚广泛使用。临床上相关的青蒿素耐药性尚未见报道,但有可能出现。为了解疟原虫如何对这种药物产生耐药性,我们研究了鼠疟原虫约氏疟原虫对青蒿素的耐药性。青蒿素耐药株(ART)对青蒿素的敏感性比敏感的NS株低约四倍,在体外积累的放射性标记药物少43%(P < 0.01)。在寄生虫体内,该药物在两种菌株中似乎与相同的寄生虫蛋白发生反应。翻译控制肿瘤蛋白是青蒿素的靶蛋白之一,在两种菌株之间没有差异。未发现DNA序列差异,但发现耐药株表达的蛋白比敏感株多2.5倍(P < 0.01)。因此,约氏疟原虫中青蒿素耐药性的表型似乎是多因素的。